No-Spa Forte Neo (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No‑Spa Forte Neo, is a phosphodiesterase inhibitor presented as an oral dosage form for systemic use. It is employed to relieve abdominal and gastrointestinal cramping, biliary colic, urinary tract spasm, and dysmenorrhea in adult patients and is indicated for both acute and chronic episodes.

GNH USA supplies No‑Spa Forte Neo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The firm follows stringent quality standards and provides regulatory‑approved batches to meet the needs of global healthcare providers.

Drotaverine Hydrochloride is an antispasmodic that relaxes smooth muscle in the gastrointestinal, biliary, urinary and uterine systems. - Abdominal and gastrointestinal cramping: reduces the intensity and frequency of painful muscle contractions in the gut. - Biliary colic: alleviates pain caused by gallbladder muscle spasm during bile flow obstruction. - Urinary tract spasm: relaxes bladder and ureter smooth muscle to ease discomfort and urgency. - Dysmenorrhea: diminishes menstrual pain by relaxing uterine smooth muscle during the menstrual cycle.

Adverse reactions to Drotaverine Hydrochloride are generally mild but can include more serious events.

Common Side Effects: - Nausea - Dizziness - Headache - Dry mouth - Hypotension - Blurred vision

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or angioedema - Severe hypotension leading to fainting - Cardiac arrhythmias - Hepatic enzyme elevation - Blood dyscrasias (e.g., neutropenia, thrombocytopenia)

When prescribing Drotaverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust use in patients with significant impairment. - Use cautiously in cardiovascular disease: monitor blood pressure and heart rate. - Avoid in known hypersensitivity to drotaverine or excipients. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Concomitant use with other smooth‑muscle relaxants: may increase antispasmodic effect. - Store below 25°C: keep in the original pack, protect from moisture.

Drotaverine Hydrochloride may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other phosphodiesterase inhibitors: risk of excessive smooth‑muscle relaxation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drotaverine plasma levels. - Anticholinergic agents: additive antispasmodic effect leading to severe constipation.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: potential additive hypotensive effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation. - Diuretics: monitor electrolyte balance, especially potassium. - Antidepressants affecting serotonin: observe for rare serotonin syndrome signs.